{ "name": "AstraZeneca PLC", "slug": "astrazeneca-plc", "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.", "status": "complete", "updated_at": "2026-08-05T23:23:46Z", "nasdaq_status": "retrieved", "latest_market": "2026-08-05: stängning 1545.50, volym 1557541", "mfn_status": "retrieved", "mfn_count": 1, "nasdaq_reports_status": "retrieved", "reports": { "available": true, "url": "/company/astrazeneca-plc/reports", "count": 15, "nasdaq_count": 14, "mfn_fallback_count": 1, "items": [ { "report_key": "2026:annual", "period_label": "2026 Årsredovisning", "date": "2026-02-25", "title": "Årsredovisning 2026", "original_title": "AstraZeneca: Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission", "category": "annual-report", "source": "MFN fallback", "source_class": "mfn", "source_url": "https://mfn.se/cis/a/astrazeneca/astrazeneca-filing-of-annual-report-on-form-20-f-with-the-us-securities-and-exchange-commission-e7642acb", "language": "en", "report_type": "annual-report", "fiscal_year": 2026, "quarter": "annual", "documents": [ { "doc_id": "mfn-fallback-arsredovisning-2026", "title": "Årsredovisning 2026", "source": "MFN fallback", "source_class": "mfn", "source_url": "https://mfn.se/cis/a/astrazeneca/astrazeneca-filing-of-annual-report-on-form-20-f-with-the-us-securities-and-exchange-commission-e7642acb", "date": "2026-02-25", "period": "2026-annual", "form_type": "annual-report", "report_key": "2026:annual", "filename": "release.txt", "text_chars": 9770, "sha256": "4213b681def7f0bcb4dc2fc5cf00eb29424d35690292be7a464a48c457777cff", "url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026", "txt_url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/part-001.html", "chars": 9770 } ] } ], "alternatives": [] }, { "report_key": "2026:q2", "period_label": "2026 Q2", "date": "2026-07-27", "title": "Kvartalsrapport Q2 2026", "original_title": "Half-year Financial Report", "category": "Half Year financial report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b9eba205211cc6b46064a369424acb25b&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026", "title": "Kvartalsrapport Q2 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a549985d90a9c3e03c64f2628a9fd36bb", "date": "2026-07-27", "period": "2026-q2", "form_type": "interim-report", "report_key": "2026:q2", "filename": "FINAL_-_26_JUL_AZN_2026_Q2_-_Announcement.pdf", "text_chars": 148994, "sha256": "49da44dc4c459daeb44d39186f1d0ea3a197ccd18b202f691782fa4a0c83753b", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html", "chars": 148994 } ] } ], "alternatives": [] }, { "report_key": "2026:q1", "period_label": "2026 Q1", "date": "2026-04-29", "title": "Kvartalsrapport Q1 2026", "original_title": "1st Quarter Results", "category": "Interim report (Q1 and Q3)", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bdd9ce7a1528b2e8b67e99a7adf0249cd&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2026, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a2a52657347f9a897ecca69cecd31b015", "date": "2026-04-29", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "POST_DC_-_28_APR_AZN_2026_Q1_-_Announcement.pdf", "text_chars": 114348, "sha256": "9cd13c17549a1e83e860c6b713be2fd22f2d7e870c10ff485d067e2bb81b8d65", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 114348 } ] } ], "alternatives": [] }, { "report_key": "2025:annual", "period_label": "2025 Årsredovisning", "date": "2026-02-24", "title": "Årsredovisning 2025", "original_title": "Annual Financial Report", "category": "Annual Financial Report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=bee501d54e0f7ff39fa376ba741a1c22a&lang=en&src=listed", "language": "en", "report_type": "annual-report", "fiscal_year": 2025, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7bfe2ec257ad4f4cb110977f3d64c512", "date": "2026-02-24", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "02245634.pdf", "text_chars": 2357, "sha256": "a381ef16b21d3c2400de8cb47412c2d68353513c8e441c7e6b581d16a26f97a5", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 2357 } ] } ], "alternatives": [] }, { "report_key": "2025:q4", "period_label": "2025 Q4", "date": "2026-02-10", "title": "Kvartalsrapport Q4 2025", "original_title": "Final Results", "category": "Financial Statement Release", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b9ce58d23cf2bde014b1c17b20cbd2186&lang=en&src=listed", "language": "en", "report_type": "year-end-report", "fiscal_year": 2025, "quarter": "q4", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "http://www.rns-pdf.londonstockexchange.com/rns/3227S_1-2026-2-9.pdf", "date": "2026-02-10", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "http_www.rns-pdf.londonstockexchange.com_rns_3227S_1-2026-2-9.pdf", "text_chars": 138705, "sha256": "568ede7aadd8f7e50cc4b6eec6922dc3c9fff855e49eaa2516093e79fe8ac679", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 138705 } ] } ], "alternatives": [] }, { "report_key": "2025:q3", "period_label": "2025 Q3", "date": "2025-11-06", "title": "Kvartalsrapport Q3 2025", "original_title": "9M and Q3 2025 results", "category": "Interim report (Q1 and Q3)", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b4aea0d8e933dd0ccac66c2e3be2b64d0&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a6b0514be8a0eb722470815d6c48541c9", "date": "2025-11-06", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "11065940.pdf", "text_chars": 127823, "sha256": "de460cb4b01ef45d4df0b0a2bce97af47104fafef078983f3ecd5594fc0a97ad", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 127823 } ] } ], "alternatives": [] }, { "report_key": "2025:q2", "period_label": "2025 Q2", "date": "2025-07-29", "title": "Kvartalsrapport Q2 2025", "original_title": "H1 and Q2 2025 results", "category": "Half Year financial report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b7ed7bd074a1dd53b1d4293bfab089e69&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad088f09125d78d4ca4a8b44606420548", "date": "2025-07-29", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "H1_and_Q2_2025_results.pdf", "text_chars": 144742, "sha256": "bccbf955cce93458737d6e0691237335077ee0ef556b18b9daa56e5495ddb466", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 144742 } ] } ], "alternatives": [] }, { "report_key": "2025:q1", "period_label": "2025 Q1", "date": "2025-04-29", "title": "Kvartalsrapport Q1 2025", "original_title": "1st Quarter Results", "category": "Interim report (Q1 and Q3)", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b18e7a2364eba4adf58e367470238a35b&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2025, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aceea43c3a8d3a0d6df16bd92a6ff0bc6", "date": "2025-04-29", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "04294155.pdf", "text_chars": 119801, "sha256": "24e40bba74661bdfda2252726f5d432768ab8195cc78150db849c00fd4e523dd", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 119801 } ] } ], "alternatives": [] }, { "report_key": "2024:annual", "period_label": "2024 Årsredovisning", "date": "2025-02-18", "title": "Årsredovisning 2024", "original_title": "Annual Financial Report", "category": "Annual Financial Report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=baa135dbe78c91b3922991707e9d4b7c1&lang=en&src=listed", "language": "en", "report_type": "annual-report", "fiscal_year": 2024, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab50172710d60f24ca9c9d9f8ae3eddb3", "date": "2025-02-18", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "02188545.pdf", "text_chars": 2393, "sha256": "6005163cf2b1f4e02004c48c7b56020ea7984bc886f4b099f1aa9387797c20fa", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 2393 } ] } ], "alternatives": [] }, { "report_key": "2024:q3", "period_label": "2024 Q3", "date": "2024-11-12", "title": "Kvartalsrapport Q3 2024", "original_title": "9M and Q3 2024 Results", "category": "Interim report (Q1 and Q3)", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b3046f86ab069a25d787d28291989e55c&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7d85580eb0dd41ae6cdf74ab1a011e2e", "date": "2024-11-12", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "11125809.pdf", "text_chars": 137431, "sha256": "42cf108fb5d0339a59dc2451cf13694331a0eb6e135fdf48a0bc99e46e99e281", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 137431 } ] } ], "alternatives": [] }, { "report_key": "2024:q2", "period_label": "2024 Q2", "date": "2024-07-25", "title": "Kvartalsrapport Q2 2024", "original_title": "Half-year Report", "category": "Half Year financial report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b18b8cfb1a23fdae62f030497b6a14b54&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2024, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a9a9ed29bfd6832e30f8d5ad48b31be44", "date": "2024-07-25", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "07258987.pdf", "text_chars": 155942, "sha256": "e10f937783d2e317ed8d9ec7787f1ec1bd6eec0a1e670d13d4d7e774d999b947", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 155942 } ] } ], "alternatives": [] }, { "report_key": "2023:annual", "period_label": "2023 Årsredovisning", "date": "2024-02-20", "title": "Årsredovisning 2023", "original_title": "Annual Financial Report", "category": "Annual Financial Report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b888ddca0456c627907feb7996f4d70e7&lang=en&src=listed", "language": "en", "report_type": "annual-report", "fiscal_year": 2023, "quarter": "annual", "documents": [ { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aefd2ab38ab7fc19764b798b153be4f7d", "date": "2024-02-20", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "02201886.pdf", "text_chars": 2641, "sha256": "c7a4fef5239d72026465eae25c5cce38739473ea26853573757bc43f4d2f0f75", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 2641 } ] } ], "alternatives": [] }, { "report_key": "2023:q3", "period_label": "2023 Q3", "date": "2023-11-09", "title": "Kvartalsrapport Q3 2023", "original_title": "9M and Q3 2023 results", "category": "Interim report (Q1 and Q3)", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b9f7876ae92f1188ef2574bdc43934a95&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q3", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a9fdf538c261c8884d36da766d1ac9718", "date": "2023-11-09", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "11091395.pdf", "text_chars": 149318, "sha256": "bf9cb364e4c58495b8c5fe38fd83bcca98ce79007acfd745f1f5c9702aa68b12", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 149318 } ] } ], "alternatives": [] }, { "report_key": "2023:q2", "period_label": "2023 Q2", "date": "2023-07-28", "title": "Kvartalsrapport Q2 2023", "original_title": "Half-year Report", "category": "Half Year financial report", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b7cf369050e9c05d1cc06a2df3c31169d&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q2", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab79b52fc3e3f6b753469465c818d7410", "date": "2023-07-28", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "07289280.pdf", "text_chars": 158635, "sha256": "f02f5f8ba9057106933d59b5005aa211b360551919be8f561e3c8b973a841a24", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 158635 } ] } ], "alternatives": [] }, { "report_key": "2023:q1", "period_label": "2023 Q1", "date": "2023-06-01", "title": "Kvartalsrapport Q1 2023", "original_title": "Block listing Interim Review", "category": "Interim report (Q1 and Q3)", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://view.news.eu.nasdaq.com/view?id=b8d7dada127ea594d4193b469c12f001c&lang=en&src=listed", "language": "en", "report_type": "interim-report", "fiscal_year": 2023, "quarter": "q1", "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a032c58d210d62745c6d35441c52993b2", "date": "2023-06-01", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "06017034.pdf", "text_chars": 2351, "sha256": "011c7d3ad087ef585142fcc7b59cc76e4831cf91ef22cc2479af54629cd16ce6", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 2351 } ] } ], "alternatives": [] } ] }, "report_count": 15, "nasdaq_report_count": 14, "mfn_fallback_count": 1, "sec_status": "skipped", "sec_count": 0, "fi_status": "retrieved", "fi_summary": { "company": "AstraZeneca PLC", "identity": { "issuer": "AstraZeneca PLC", "lei": "PY6ZZQWO2IZFZC3IOL08", "source": "FI insynsregister", "row_count": 28, "score": 118.0, "status": "resolved", "requested_company": "AstraZeneca PLC", "query": "AstraZeneca PLC", "candidate_count": 348 }, "period": { "from": "2024-08-05", "to": "2026-08-05", "years": 2 }, "generated_at": "2026-08-05T21:01:06Z", "insider": { "transactions": 28, "all_export_rows": 28, "acquisitions": 11, "disposals": 3, "other": 14, "acquisition_value_sek": 0, "disposal_value_sek": 0, "characters": { "Avyttring": 3, "Förvärv": 11, "Gåva lämnad": 3, "Gåva mottagen": 1, "Tilldelning": 8, "Utdelning mottagen": 2 } }, "short_selling": { "aggregate_percent": 0.3, "current_public_positions": 0, "historical_changes": 0, "current_position_sum_over_0_5": 0 }, "sources": { "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/", "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/" } }, "warnings": [], "source_identity": { "nasdaq_reports": { "slug": "azn", "instrument_id": "TX271", "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/azn?id=TX271" }, "mfn": { "status": "resolved", "company_name": "AstraZeneca", "expected_name": "AstraZeneca PLC", "match_score": 100.0, "slug": "astrazeneca", "url": "https://mfn.se/all/a/astrazeneca", "metadata": { "country": "Storbritannien", "list": "FTSE 100", "sector": "Hälsovård", "industry": "Läkemedel & Handel", "website": "https://mb.cision.com/Main/309/4377686/4203207.pdf" }, "ticker_candidates": [], "attempts": [ { "slug": "astrazeneca-plc", "url": "https://mfn.se/all/a/astrazeneca-plc", "status": "identity_mismatch", "title": "", "score": 0.0 } ] }, "sec": null, "nasdaq": { "instrument_id": "TX271", "asset_class": "SHARES", "isin": "GB0009895292", "symbol": "AZN", "company": "AstraZeneca", "market": null, "last_sale_price": "SEK 1,545.50", "time_as_of": "2026-08-05" }, "finansinspektionen": { "issuer": "AstraZeneca PLC", "lei": "PY6ZZQWO2IZFZC3IOL08", "source": "FI insynsregister", "row_count": 28, "score": 118.0, "status": "resolved", "requested_company": "AstraZeneca PLC", "query": "AstraZeneca PLC", "candidate_count": 348 } }, "documents": [ { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026", "title": "Kvartalsrapport Q2 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a549985d90a9c3e03c64f2628a9fd36bb", "date": "2026-07-27", "period": "2026-q2", "form_type": "interim-report", "report_key": "2026:q2", "filename": "FINAL_-_26_JUL_AZN_2026_Q2_-_Announcement.pdf", "text_chars": 148994, "sha256": "49da44dc4c459daeb44d39186f1d0ea3a197ccd18b202f691782fa4a0c83753b", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html", "chars": 148994 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026", "title": "Kvartalsrapport Q1 2026", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a2a52657347f9a897ecca69cecd31b015", "date": "2026-04-29", "period": "2026-q1", "form_type": "interim-report", "report_key": "2026:q1", "filename": "POST_DC_-_28_APR_AZN_2026_Q1_-_Announcement.pdf", "text_chars": 114348, "sha256": "9cd13c17549a1e83e860c6b713be2fd22f2d7e870c10ff485d067e2bb81b8d65", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html", "chars": 114348 } ] }, { "doc_id": "mfn-fallback-arsredovisning-2026", "title": "Årsredovisning 2026", "source": "MFN fallback", "source_class": "mfn", "source_url": "https://mfn.se/cis/a/astrazeneca/astrazeneca-filing-of-annual-report-on-form-20-f-with-the-us-securities-and-exchange-commission-e7642acb", "date": "2026-02-25", "period": "2026-annual", "form_type": "annual-report", "report_key": "2026:annual", "filename": "release.txt", "text_chars": 9770, "sha256": "4213b681def7f0bcb4dc2fc5cf00eb29424d35690292be7a464a48c457777cff", "url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026", "txt_url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/mfn-fallback-arsredovisning-2026/part-001.html", "chars": 9770 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2025", "title": "Årsredovisning 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7bfe2ec257ad4f4cb110977f3d64c512", "date": "2026-02-24", "period": "2025-annual", "form_type": "annual-report", "report_key": "2025:annual", "filename": "02245634.pdf", "text_chars": 2357, "sha256": "a381ef16b21d3c2400de8cb47412c2d68353513c8e441c7e6b581d16a26f97a5", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2025/part-001.html", "chars": 2357 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025", "title": "Kvartalsrapport Q4 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "http://www.rns-pdf.londonstockexchange.com/rns/3227S_1-2026-2-9.pdf", "date": "2026-02-10", "period": "2025-q4", "form_type": "year-end-report", "report_key": "2025:q4", "filename": "http_www.rns-pdf.londonstockexchange.com_rns_3227S_1-2026-2-9.pdf", "text_chars": 138705, "sha256": "568ede7aadd8f7e50cc4b6eec6922dc3c9fff855e49eaa2516093e79fe8ac679", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html", "chars": 138705 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025", "title": "Kvartalsrapport Q3 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a6b0514be8a0eb722470815d6c48541c9", "date": "2025-11-06", "period": "2025-q3", "form_type": "interim-report", "report_key": "2025:q3", "filename": "11065940.pdf", "text_chars": 127823, "sha256": "de460cb4b01ef45d4df0b0a2bce97af47104fafef078983f3ecd5594fc0a97ad", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html", "chars": 127823 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025", "title": "Kvartalsrapport Q2 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ad088f09125d78d4ca4a8b44606420548", "date": "2025-07-29", "period": "2025-q2", "form_type": "interim-report", "report_key": "2025:q2", "filename": "H1_and_Q2_2025_results.pdf", "text_chars": 144742, "sha256": "bccbf955cce93458737d6e0691237335077ee0ef556b18b9daa56e5495ddb466", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html", "chars": 144742 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025", "title": "Kvartalsrapport Q1 2025", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aceea43c3a8d3a0d6df16bd92a6ff0bc6", "date": "2025-04-29", "period": "2025-q1", "form_type": "interim-report", "report_key": "2025:q1", "filename": "04294155.pdf", "text_chars": 119801, "sha256": "24e40bba74661bdfda2252726f5d432768ab8195cc78150db849c00fd4e523dd", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html", "chars": 119801 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2024", "title": "Årsredovisning 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab50172710d60f24ca9c9d9f8ae3eddb3", "date": "2025-02-18", "period": "2024-annual", "form_type": "annual-report", "report_key": "2024:annual", "filename": "02188545.pdf", "text_chars": 2393, "sha256": "6005163cf2b1f4e02004c48c7b56020ea7984bc886f4b099f1aa9387797c20fa", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2024/part-001.html", "chars": 2393 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024", "title": "Kvartalsrapport Q3 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a7d85580eb0dd41ae6cdf74ab1a011e2e", "date": "2024-11-12", "period": "2024-q3", "form_type": "interim-report", "report_key": "2024:q3", "filename": "11125809.pdf", "text_chars": 137431, "sha256": "42cf108fb5d0339a59dc2451cf13694331a0eb6e135fdf48a0bc99e46e99e281", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html", "chars": 137431 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024", "title": "Kvartalsrapport Q2 2024", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a9a9ed29bfd6832e30f8d5ad48b31be44", "date": "2024-07-25", "period": "2024-q2", "form_type": "interim-report", "report_key": "2024:q2", "filename": "07258987.pdf", "text_chars": 155942, "sha256": "e10f937783d2e317ed8d9ec7787f1ec1bd6eec0a1e670d13d4d7e774d999b947", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html", "chars": 155942 } ] }, { "doc_id": "nasdaq-nordic-arsredovisning-2023", "title": "Årsredovisning 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/aefd2ab38ab7fc19764b798b153be4f7d", "date": "2024-02-20", "period": "2023-annual", "form_type": "annual-report", "report_key": "2023:annual", "filename": "02201886.pdf", "text_chars": 2641, "sha256": "c7a4fef5239d72026465eae25c5cce38739473ea26853573757bc43f4d2f0f75", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-arsredovisning-2023/part-001.html", "chars": 2641 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023", "title": "Kvartalsrapport Q3 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a9fdf538c261c8884d36da766d1ac9718", "date": "2023-11-09", "period": "2023-q3", "form_type": "interim-report", "report_key": "2023:q3", "filename": "11091395.pdf", "text_chars": 149318, "sha256": "bf9cb364e4c58495b8c5fe38fd83bcca98ce79007acfd745f1f5c9702aa68b12", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html", "chars": 149318 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023", "title": "Kvartalsrapport Q2 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/ab79b52fc3e3f6b753469465c818d7410", "date": "2023-07-28", "period": "2023-q2", "form_type": "interim-report", "report_key": "2023:q2", "filename": "07289280.pdf", "text_chars": 158635, "sha256": "f02f5f8ba9057106933d59b5005aa211b360551919be8f561e3c8b973a841a24", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html", "chars": 158635 } ] }, { "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023", "title": "Kvartalsrapport Q1 2023", "source": "Nasdaq Nordic", "source_class": "nasdaq-report", "source_url": "https://attachment.news.eu.nasdaq.com/a032c58d210d62745c6d35441c52993b2", "date": "2023-06-01", "period": "2023-q1", "form_type": "interim-report", "report_key": "2023:q1", "filename": "06017034.pdf", "text_chars": 2351, "sha256": "011c7d3ad087ef585142fcc7b59cc76e4831cf91ef22cc2479af54629cd16ce6", "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023", "txt_url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html", "chars": 2351 } ] }, { "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata", "title": "MFN bolagssida och bolagsmetadata", "source": "MFN", "source_class": "mfn", "source_url": "https://mfn.se/all/a/astrazeneca", "date": null, "period": null, "form_type": "company-page", "report_key": null, "filename": "company.txt", "text_chars": 17911, "sha256": "8ff8dc15e3900dc647d1bbe1eacfae956eb008816ce839e05e323c584442cf01", "url": "/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata", "txt_url": "/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "absolute_txt_url": "https://spela.port0.org/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt", "parts": [ { "number": 1, "url": "/company/astrazeneca-plc/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html", "chars": 17911 } ] } ], "market_files": [ { "label": "Nasdaq kurshistorik CSV", "url": "/company/astrazeneca-plc/market/history.csv", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/history.csv" }, { "label": "Nasdaq kurshistorik JSON", "url": "/company/astrazeneca-plc/market/history.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/history.json" }, { "label": "Nasdaq manifest JSON", "url": "/company/astrazeneca-plc/market/manifest.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/manifest.json" }, { "label": "Nasdaq instrumentidentitet JSON", "url": "/company/astrazeneca-plc/market/instrument.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/instrument.json" }, { "label": "SEC Company Facts JSON", "url": "/company/astrazeneca-plc/market/sec-companyfacts.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/sec-companyfacts.json" }, { "label": "SEC filing-manifest JSON", "url": "/company/astrazeneca-plc/market/sec-manifest.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/sec-manifest.json" }, { "label": "SEC sammanfattning JSON", "url": "/company/astrazeneca-plc/market/sec-summary.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/sec-summary.json" }, { "label": "MFN manifest JSON", "url": "/company/astrazeneca-plc/market/mfn-manifest.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/mfn-manifest.json" }, { "label": "Nasdaq rapportmanifest JSON", "url": "/company/astrazeneca-plc/market/nasdaq-reports-manifest.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc/market/nasdaq-reports-manifest.json" } ], "sec_facts": { "status": "summarized", "entity_name": "ASTRAZENECA PLC", "cik": 901832, "metrics": [ { "label": "Nettoresultat", "taxonomy": "ifrs-full", "concept": "ProfitLoss", "description": null, "label_original": null, "facts": [ { "fy": 2025, "fp": "FY", "form": "20-F", "start": "2025-01-01", "end": "2025-12-31", "filed": "2026-02-24", "value": 10233000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2025" }, { "fy": 2025, "fp": "FY", "form": "20-F", "start": "2024-01-01", "end": "2024-12-31", "filed": "2026-02-24", "value": 7041000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2024" }, { "fy": 2025, "fp": "FY", "form": "20-F", "start": "2023-01-01", "end": "2023-12-31", "filed": "2026-02-24", "value": 5961000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2023" }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": "2025-01-01", "end": "2025-06-30", "filed": "2025-07-29", "value": 5369000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": null }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": "2024-01-01", "end": "2024-06-30", "filed": "2025-07-29", "value": 4108000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": null }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": "2024-01-01", "end": "2024-12-31", "filed": "2025-02-18", "value": 7041000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": null }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": "2023-01-01", "end": "2023-12-31", "filed": "2025-02-18", "value": 5961000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": null }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": "2022-01-01", "end": "2022-12-31", "filed": "2025-02-18", "value": 3293000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": "CY2022" }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": "2024-01-01", "end": "2024-06-30", "filed": "2024-07-25", "value": 4108000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": null }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": "2023-01-01", "end": "2023-06-30", "filed": "2024-07-25", "value": 3624000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": "2023-01-01", "end": "2023-12-31", "filed": "2024-02-20", "value": 5961000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": "2022-01-01", "end": "2022-12-31", "filed": "2024-02-20", "value": 3293000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": "2021-01-01", "end": "2021-12-31", "filed": "2024-02-20", "value": 115000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": "CY2021" }, { "fy": 2023, "fp": "Q2", "form": "6-K", "start": "2023-01-01", "end": "2023-06-30", "filed": "2023-07-28", "value": 3624000000, "unit": "USD", "accession": "0001104659-23-085104", "frame": null }, { "fy": 2023, "fp": "Q2", "form": "6-K", "start": "2022-01-01", "end": "2022-06-30", "filed": "2023-07-28", "value": 748000000, "unit": "USD", "accession": "0001104659-23-085104", "frame": null }, { "fy": 2022, "fp": "FY", "form": "20-F", "start": "2022-01-01", "end": "2022-12-31", "filed": "2023-02-21", "value": 3293000000, "unit": "USD", "accession": "0001104659-23-023818", "frame": null } ] }, { "label": "Tillgångar", "taxonomy": "ifrs-full", "concept": "Assets", "description": null, "label_original": null, "facts": [ { "fy": 2025, "fp": "FY", "form": "20-F", "start": null, "end": "2025-12-31", "filed": "2026-02-24", "value": 114074000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2025Q4I" }, { "fy": 2025, "fp": "FY", "form": "20-F", "start": null, "end": "2024-12-31", "filed": "2026-02-24", "value": 104035000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2024Q4I" }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": null, "end": "2025-06-30", "filed": "2025-07-29", "value": 112422000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": "CY2025Q2I" }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": null, "end": "2024-12-31", "filed": "2025-07-29", "value": 104035000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": null }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": null, "end": "2024-06-30", "filed": "2025-07-29", "value": 104340000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": "CY2024Q2I" }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": null, "end": "2024-12-31", "filed": "2025-02-18", "value": 104035000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": null }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": null, "end": "2023-12-31", "filed": "2025-02-18", "value": 101119000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": "CY2023Q4I" }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": null, "end": "2022-12-31", "filed": "2025-02-18", "value": 96483000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": "CY2022Q4I" }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": null, "end": "2024-06-30", "filed": "2024-07-25", "value": 104340000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": null }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": null, "end": "2023-12-31", "filed": "2024-07-25", "value": 101119000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": null }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": null, "end": "2023-06-30", "filed": "2024-07-25", "value": 96543000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": "CY2023Q2I" }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": null, "end": "2023-12-31", "filed": "2024-02-20", "value": 101119000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": null, "end": "2022-12-31", "filed": "2024-02-20", "value": 96483000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": null, "end": "2021-12-31", "filed": "2024-02-20", "value": 105363000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": "CY2021Q4I" }, { "fy": 2023, "fp": "Q2", "form": "6-K", "start": null, "end": "2023-06-30", "filed": "2023-07-28", "value": 96543000000, "unit": "USD", "accession": "0001104659-23-085104", "frame": null }, { "fy": 2023, "fp": "Q2", "form": "6-K", "start": null, "end": "2022-12-31", "filed": "2023-07-28", "value": 96483000000, "unit": "USD", "accession": "0001104659-23-085104", "frame": null } ] }, { "label": "Skulder", "taxonomy": "ifrs-full", "concept": "Liabilities", "description": null, "label_original": null, "facts": [ { "fy": 2025, "fp": "FY", "form": "20-F", "start": null, "end": "2025-12-31", "filed": "2026-02-24", "value": 65355000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2025Q4I" }, { "fy": 2025, "fp": "FY", "form": "20-F", "start": null, "end": "2024-12-31", "filed": "2026-02-24", "value": 63164000000, "unit": "USD", "accession": "0001104659-26-019130", "frame": "CY2024Q4I" }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": null, "end": "2025-06-30", "filed": "2025-07-29", "value": 67612000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": "CY2025Q2I" }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": null, "end": "2024-12-31", "filed": "2025-07-29", "value": 63164000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": null }, { "fy": 2025, "fp": "Q2", "form": "6-K", "start": null, "end": "2024-06-30", "filed": "2025-07-29", "value": 64742000000, "unit": "USD", "accession": "0001104659-25-071432", "frame": "CY2024Q2I" }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": null, "end": "2024-12-31", "filed": "2025-02-18", "value": 63164000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": null }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": null, "end": "2023-12-31", "filed": "2025-02-18", "value": 61953000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": "CY2023Q4I" }, { "fy": 2024, "fp": "FY", "form": "20-F", "start": null, "end": "2022-12-31", "filed": "2025-02-18", "value": 59425000000, "unit": "USD", "accession": "0001104659-25-014750", "frame": "CY2022Q4I" }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": null, "end": "2024-06-30", "filed": "2024-07-25", "value": 64742000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": null }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": null, "end": "2023-12-31", "filed": "2024-07-25", "value": 61953000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": null }, { "fy": 2024, "fp": "Q2", "form": "6-K", "start": null, "end": "2023-06-30", "filed": "2024-07-25", "value": 59127000000, "unit": "USD", "accession": "0001104659-24-082531", "frame": "CY2023Q2I" }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": null, "end": "2023-12-31", "filed": "2024-02-20", "value": 61953000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": null, "end": "2022-12-31", "filed": "2024-02-20", "value": 59425000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": null }, { "fy": 2023, "fp": "FY", "form": "20-F", "start": null, "end": "2021-12-31", "filed": "2024-02-20", "value": 66076000000, "unit": "USD", "accession": "0001104659-24-025553", "frame": "CY2021Q4I" }, { "fy": 2023, "fp": "Q2", "form": "6-K", "start": null, "end": "2023-06-30", "filed": "2023-07-28", "value": 59127000000, "unit": "USD", "accession": "0001104659-23-085104", "frame": null }, { "fy": 2023, "fp": "Q2", "form": "6-K", "start": null, "end": "2022-12-31", "filed": "2023-07-28", "value": 59425000000, "unit": "USD", "accession": "0001104659-23-085104", "frame": null } ] } ] }, "morningstar": { "configured": true, "status": "retrieved", "captured_at": "2026-08-02T14:43:39Z", "view_count": 4, "url": "/company/astrazeneca-plc/morningstar", "path": "D:\\Web\\aktieanalys\\public\\company\\.astrazeneca-plc.tmp\\morningstar", "files": [ "index.html", "summary.txt", "screenshot.png" ] }, "finansinspektionen": { "available": true, "status": "retrieved", "url": "/company/astrazeneca-plc/finansinspektionen", "transaction_count": 28, "aggregate_short_percent": 0.3, "files": [ { "filename": "summary.json", "label": "Sammanfattning JSON", "url": "summary.json" }, { "filename": "insider-transactions.csv", "label": "Insynstransaktioner CSV", "url": "insider-transactions.csv" }, { "filename": "insider-transactions.json", "label": "Insynstransaktioner JSON", "url": "insider-transactions.json" }, { "filename": "short-current.json", "label": "Aktuella blankningspositioner JSON", "url": "short-current.json" }, { "filename": "short-history.json", "label": "Historiska blankningspositioner JSON", "url": "short-history.json" }, { "filename": "short-aggregate.json", "label": "Aggregerad blankning JSON", "url": "short-aggregate.json" }, { "filename": "manifest.json", "label": "Hämtningsmanifest JSON", "url": "manifest.json" } ] }, "llms_url": "/company/astrazeneca-plc/llms.txt", "json_url": "/company/astrazeneca-plc/company.json", "document_index_url": "/company/astrazeneca-plc/documents.json", "absolute_url": "https://spela.port0.org/company/astrazeneca-plc" }